Matches in Wikidata for { <http://www.wikidata.org/entity/Q94146096> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- Q94146096 description "article scientifique publié en 2018" @default.
- Q94146096 description "wetenschappelijk artikel" @default.
- Q94146096 description "наукова стаття" @default.
- Q94146096 name "ATIM-24. INTERIM RESULTS OF A PHASE II MULTICENTER STUDY OF THE CONDITIONALLY REPLICATIVE ONCOLYTIC ADENOVIRUS DNX-2401 WITH PEMBROLIZUMAB (KEYTRUDA) FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192)" @default.
- Q94146096 name "ATIM-24. INTERIM RESULTS OF A PHASE II MULTICENTER STUDY OF THE CONDITIONALLY REPLICATIVE ONCOLYTIC ADENOVIRUS DNX-2401 WITH PEMBROLIZUMAB (KEYTRUDA) FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192)" @default.
- Q94146096 type Item @default.
- Q94146096 label "ATIM-24. INTERIM RESULTS OF A PHASE II MULTICENTER STUDY OF THE CONDITIONALLY REPLICATIVE ONCOLYTIC ADENOVIRUS DNX-2401 WITH PEMBROLIZUMAB (KEYTRUDA) FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192)" @default.
- Q94146096 label "ATIM-24. INTERIM RESULTS OF A PHASE II MULTICENTER STUDY OF THE CONDITIONALLY REPLICATIVE ONCOLYTIC ADENOVIRUS DNX-2401 WITH PEMBROLIZUMAB (KEYTRUDA) FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192)" @default.
- Q94146096 prefLabel "ATIM-24. INTERIM RESULTS OF A PHASE II MULTICENTER STUDY OF THE CONDITIONALLY REPLICATIVE ONCOLYTIC ADENOVIRUS DNX-2401 WITH PEMBROLIZUMAB (KEYTRUDA) FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192)" @default.
- Q94146096 prefLabel "ATIM-24. INTERIM RESULTS OF A PHASE II MULTICENTER STUDY OF THE CONDITIONALLY REPLICATIVE ONCOLYTIC ADENOVIRUS DNX-2401 WITH PEMBROLIZUMAB (KEYTRUDA) FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192)" @default.
- Q94146096 P1433 Q94146096-2B588AC5-1DBE-4DB9-AC56-4E4EC19D63E8 @default.
- Q94146096 P1476 Q94146096-6E79086F-E6F7-44BE-BBB4-6E4C12905A8C @default.
- Q94146096 P2093 Q94146096-0B737158-75E8-4325-9F8D-A43644ECF920 @default.
- Q94146096 P2093 Q94146096-14D7BF33-2328-4633-B817-1280F33D4AAB @default.
- Q94146096 P2093 Q94146096-1BF6C7C5-E1CB-49BE-B273-158A7657A635 @default.
- Q94146096 P2093 Q94146096-2825B9AE-88EB-4708-AA0B-E3A5566AB282 @default.
- Q94146096 P2093 Q94146096-345CAFF6-06F5-408A-BA53-44ECFDD16553 @default.
- Q94146096 P2093 Q94146096-3A6D3CD5-6667-4254-AF2E-20F5AEE093F4 @default.
- Q94146096 P2093 Q94146096-3A96DD7A-2F6D-4EE0-BEAA-7E73AA70A436 @default.
- Q94146096 P2093 Q94146096-3E3A9759-BDEA-4880-AB4F-0798F818B677 @default.
- Q94146096 P2093 Q94146096-5A8DE9EA-DBC3-4DA4-9A57-83A14397BAA1 @default.
- Q94146096 P2093 Q94146096-76A68260-7FC2-4C6F-BC81-46B03633555A @default.
- Q94146096 P2093 Q94146096-77760184-FAB4-46C4-A3BD-EF0349DF384F @default.
- Q94146096 P2093 Q94146096-88BE2283-F9DD-4645-AAFB-926B5FF2D257 @default.
- Q94146096 P2093 Q94146096-9CF2C170-E1C4-4D39-A548-190D5B7C44E2 @default.
- Q94146096 P2093 Q94146096-D3CEA10B-11BF-4A13-AC9A-08A89C2D4D3D @default.
- Q94146096 P2093 Q94146096-E5AFE9A4-3CBD-4552-A758-570FDE0099BB @default.
- Q94146096 P2093 Q94146096-F1583F7C-EEE9-4B02-8030-F2E6D496B5CD @default.
- Q94146096 P2093 Q94146096-FC44A2D0-F005-479D-9DF6-4BE4BCB948D9 @default.
- Q94146096 P304 Q94146096-DCA9AE71-1DCF-414D-ADF8-F725F6D4E77B @default.
- Q94146096 P31 Q94146096-2CF34CD5-AFAE-4C4C-98F8-F76AB1AA8601 @default.
- Q94146096 P356 Q94146096-2294577F-F0B7-4A32-BB0B-107E4609674D @default.
- Q94146096 P433 Q94146096-680D29C1-6803-48B6-84DF-D812ED4A5A5E @default.
- Q94146096 P478 Q94146096-67826E1F-A2A0-4FDE-B1F4-F76DEFA7DC09 @default.
- Q94146096 P50 Q94146096-021DC02A-1E20-4DD0-8EDA-3F94ECAED51B @default.
- Q94146096 P577 Q94146096-FD7FA104-047C-44D0-A539-8F101F72062E @default.
- Q94146096 P921 Q94146096-049FFCA0-B98C-4A2F-93E4-C7C039404C6D @default.
- Q94146096 P921 Q94146096-8DE9CD4A-1DB8-4839-857B-EA691057EB3D @default.
- Q94146096 P932 Q94146096-DFA098E3-DF1F-408B-9F48-3853DCF88321 @default.
- Q94146096 P356 NOY148.019 @default.
- Q94146096 P1433 Q15724471 @default.
- Q94146096 P1476 "ATIM-24. INTERIM RESULTS OF A PHASE II MULTICENTER STUDY OF THE CONDITIONALLY REPLICATIVE ONCOLYTIC ADENOVIRUS DNX-2401 WITH PEMBROLIZUMAB (KEYTRUDA) FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192)" @default.
- Q94146096 P2093 "Brett Ewald" @default.
- Q94146096 P2093 "Erin Mitchell" @default.
- Q94146096 P2093 "Farshad Nassiri" @default.
- Q94146096 P2093 "Frank Tufaro" @default.
- Q94146096 P2093 "Frederick Lang" @default.
- Q94146096 P2093 "Gelareh Zadeh" @default.
- Q94146096 P2093 "Howard Colman" @default.
- Q94146096 P2093 "Joanna Peterkin" @default.
- Q94146096 P2093 "Karen Gammon" @default.
- Q94146096 P2093 "Kari Anne Rowland" @default.
- Q94146096 P2093 "L Sue Frederick" @default.
- Q94146096 P2093 "Mariza Daras" @default.
- Q94146096 P2093 "Michael Vogelbaum" @default.
- Q94146096 P2093 "Morris Groves" @default.
- Q94146096 P2093 "Rohan Ramakrishna" @default.
- Q94146096 P2093 "Sheila Fulling" @default.
- Q94146096 P2093 "Shirley Ong" @default.
- Q94146096 P304 "vi6-vi6" @default.
- Q94146096 P31 Q13442814 @default.
- Q94146096 P356 "10.1093/NEUONC/NOY148.019" @default.
- Q94146096 P433 "Suppl 6" @default.
- Q94146096 P478 "20" @default.
- Q94146096 P50 Q47159504 @default.
- Q94146096 P577 "2018-11-05T00:00:00Z" @default.
- Q94146096 P921 Q13896859 @default.
- Q94146096 P921 Q282142 @default.
- Q94146096 P932 "6216134" @default.